Unknown

Dataset Information

0

A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma.

ABSTRACT:

SUBMITTER: Rosenthal A 

PROVIDER: S-EPMC4820359 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma.

Rosenthal Allison A   Kumar Shaji S   Hofmeister Craig C   Laubach Jacob J   Vij Ravi R   Dueck Amylou A   Gano Katherine K   Stewart A Keith AK  

British journal of haematology 20150925 2

Similar Datasets

Unknown Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.
| S-EPMC6982547 | biostudies-literature
Unknown Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.
| S-EPMC4045308 | biostudies-literature
Unknown An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes.
| S-EPMC4110881 | biostudies-literature
Unknown MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors.
| S-EPMC4468408 | biostudies-literature
Unknown Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.
| S-EPMC4229392 | biostudies-literature
Unknown A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors.
| S-EPMC11048245 | biostudies-literature
Unknown Chromobox2 inhibition: a novel activity of alisertib, an aurora A kinase inhibitor.
| S-EPMC12866977 | biostudies-literature
Unknown Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
| S-EPMC3867644 | biostudies-literature
Unknown Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.
| S-EPMC7731903 | biostudies-literature
Unknown Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
| S-EPMC4872349 | biostudies-literature